Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors

被引:56
作者
Abe, Koji [1 ]
Bridges, Arlene S. [1 ]
Brouwer, Kim L. R. [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
ORGANIC ANION TRANSPORTER; RAT HEPATOCYTES; HEPATIC-UPTAKE; IN-VIVO; HEPATOBILIARY TRANSPORT; DRUG CLEARANCE; OPIOID PEPTIDE; EXCRETION; BILE; PITAVASTATIN;
D O I
10.1124/dmd.108.023465
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Previous reports have indicated that in vitro biliary clearance (CIbiliary) determined in sandwich-cultured hepatocytes correlates well with in vivo CIbiliary for limited sets of compounds. The purpose of this study was 1) to determine the in vitro Clbiliary in sandwich-cultured human hepatocytes of angiotensin II receptor blockers and HMG-CoA reductase inhibitors that undergo limited metabolism and 2) to compare the predicted CIbiliary values with estimated in vivo hepatic clearance data in humans. The average biliary excretion index and in vitro intrinsic CIbiliary values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively. CIbiliary values predicted from sandwich-cultured human hepatocytes correlated with estimated in vivo hepatic clearance values based on published data (no in vivo data in humans was available for pitavastatin), and the rank order was also consistent. In conclusion, in vitro CIbiliary determined in sandwich-cultured human hepatocytes can be used to predict in vivo CIbiliary of compounds in humans.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 29 条
[1]   In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in sandwich-cultured rat hepatocytes: Comparison with in vivo biliary clearance [J].
Abe, Koji ;
Bridges, Arlene S. ;
Yue, Wei ;
Brouwer, Kim L. R. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (03) :983-990
[2]   Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport [J].
Bi, Yi-an ;
Kazolias, Diana ;
Duignan, David B. .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) :1658-1665
[3]   Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist [J].
Colussi, DM ;
Parisot, C ;
Rossolino, ML ;
Brunner, LA ;
Lefevre, GY .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (03) :214-221
[4]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[5]   Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man [J].
Flesch, G ;
Muller, P ;
Lloyd, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) :115-120
[6]  
Fujino H, 2004, ARZNEIMITTEL-FORSCH, V54, P382
[7]   In vitro-in vivo correlation of hepatobiliary drug clearance in humans [J].
Ghibellini, G. ;
Vasist, L. S. ;
Leslie, E. M. ;
Heizer, W. D. ;
Kowalsky, R. J. ;
Calvo, B. F. ;
Brouwer, K. L. R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (03) :406-413
[8]   Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin [J].
Hirano, M ;
Maeda, K ;
Matsushima, S ;
Nozaki, Y ;
Kusuhara, H ;
Sugiyama, Y .
MOLECULAR PHARMACOLOGY, 2005, 68 (03) :800-807
[9]   Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics [J].
Ho, Richard H. ;
Tirona, Rommel G. ;
Leake, Brenda F. ;
Glaeser, Hartmut ;
Lee, Wooin ;
Lemke, Christopher J. ;
Wang, Yi ;
Kim, Richard B. .
GASTROENTEROLOGY, 2006, 130 (06) :1793-1806
[10]   P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: Relevance to the hepatobiliary disposition of a model opioid peptide [J].
Hoffmaster, KA ;
Turncliff, RZ ;
LeCluyse, EL ;
Kim, RB ;
Meier, PJ ;
Brouwer, KLR .
PHARMACEUTICAL RESEARCH, 2004, 21 (07) :1294-1302